Lesley Schofield

548 total citations
12 papers, 457 citations indexed

About

Lesley Schofield is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Hematology. According to data from OpenAlex, Lesley Schofield has authored 12 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Molecular Biology and 3 papers in Hematology. Recurrent topics in Lesley Schofield's work include Multiple Sclerosis Research Studies (9 papers), Sphingolipid Metabolism and Signaling (4 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Lesley Schofield is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Sphingolipid Metabolism and Signaling (4 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Lesley Schofield collaborates with scholars based in United States, Switzerland and Canada. Lesley Schofield's co-authors include Kiyotsugu Yoshida, Carlo M. Nalin, Ralph R. Weichselbaum, Pramod S. Pandey, Sara J. Israels, Ajit Bharti, Zhi-Min Yuan, Surender Kharbanda, Satya Saxena and Donald Küfe and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neurology and Journal of Clinical Hypertension.

In The Last Decade

Lesley Schofield

12 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lesley Schofield United States 7 325 75 65 60 52 12 457
Xiaolan Yi United States 6 297 0.9× 113 1.5× 75 1.2× 76 1.3× 93 1.8× 7 537
Meng Teng Peh Singapore 8 209 0.6× 61 0.8× 65 1.0× 133 2.2× 40 0.8× 9 611
Christian Böhm Germany 11 248 0.8× 48 0.6× 92 1.4× 106 1.8× 75 1.4× 16 488
Jiayu Jin China 8 321 1.0× 36 0.5× 33 0.5× 37 0.6× 52 1.0× 12 463
Qingwen Xie China 11 205 0.6× 35 0.5× 31 0.5× 46 0.8× 93 1.8× 19 382
Manal L. Louka Egypt 12 173 0.5× 35 0.5× 45 0.7× 35 0.6× 33 0.6× 26 359
Shunlin Qu China 14 293 0.9× 93 1.2× 26 0.4× 47 0.8× 59 1.1× 21 470
Boda Zhou China 13 324 1.0× 24 0.3× 62 1.0× 52 0.9× 88 1.7× 44 554
Nermin Ali Japan 13 278 0.9× 25 0.3× 47 0.7× 64 1.1× 45 0.9× 18 506
Chuansheng Xu China 10 202 0.6× 41 0.5× 50 0.8× 63 1.1× 126 2.4× 16 401

Countries citing papers authored by Lesley Schofield

Since Specialization
Citations

This map shows the geographic impact of Lesley Schofield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lesley Schofield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lesley Schofield more than expected).

Fields of papers citing papers by Lesley Schofield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lesley Schofield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lesley Schofield. The network helps show where Lesley Schofield may publish in the future.

Co-authorship network of co-authors of Lesley Schofield

This figure shows the co-authorship network connecting the top 25 collaborators of Lesley Schofield. A scholar is included among the top collaborators of Lesley Schofield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lesley Schofield. Lesley Schofield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Hunter, Samuel F., Florian P. Thomas, Mark Cascione, et al.. (2020). Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰. Multiple Sclerosis and Related Disorders. 45. 102346–102346. 1 indexed citations
2.
Cascione, Mark, Nadia Tenenbaum, Jeanette Wendt, et al.. (2018). Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. Multiple Sclerosis and Related Disorders. 25. 50–56. 10 indexed citations
3.
Cree, Bruce, Douglas L. Arnold, Mark Cascione, et al.. (2018). Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders. 11. 1276995906–1276995906. 20 indexed citations
4.
Cascione, Mark, Jeanette Wendt, Bruce Cree, et al.. (2017). PREFERMS study: post hoc analyses of patient retention, key clinical outcomes and patient satisfaction in an African-American patient subgroup (P6.382). Neurology. 88(16_supplement). 1 indexed citations
5.
Benedict, Ralph H. B., Douglas L. Arnold, Bruce Cree, et al.. (2017). Improved processing speed in multiple sclerosis during fingolimod therapy: oral Symbol Digit Modalities Test response in PREFERMS (P4.331). Neurology. 88(16_supplement). 1 indexed citations
6.
7.
8.
Cascione, Mark, Mark S. Freedman, Mark Agius, et al.. (2014). First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(5). 620–628. 13 indexed citations
9.
10.
Neutel, Joel M., David H.G. Smith, Michael A. Weber, et al.. (2006). Efficacy of Combination Therapy With Amlodipine Besylate/Benazepril Hydrochloride for Lowering Systolic Blood Pressure in Stage 2 Hypertension. The American Journal of Geriatric Cardiology. 15(3). 142–150. 7 indexed citations
11.
Neutel, Joel M., David H.G. Smith, Michael A. Weber, et al.. (2005). Efficacy of Combination Therapy for Systolic Blood Pressure in Patients With Severe Systolic Hypertension: The Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) Study. Journal of Clinical Hypertension. 7(11). 641–646. 40 indexed citations
12.
Kharbanda, Surender, Pramod S. Pandey, Lesley Schofield, et al.. (1997). Role for Bcl-xLas an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proceedings of the National Academy of Sciences. 94(13). 6939–6942. 349 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaolan Yi Breakdown of academic impact, for papers by Meng Teng Peh Breakdown of academic impact, for papers by Christian Böhm Breakdown of academic impact, for papers by Jiayu Jin Breakdown of academic impact, for papers by Qingwen Xie Breakdown of academic impact, for papers by Manal L. Louka Breakdown of academic impact, for papers by Shunlin Qu Breakdown of academic impact, for papers by Boda Zhou Breakdown of academic impact, for papers by Nermin Ali Breakdown of academic impact, for papers by Chuansheng Xu
Rankless by CCL
2026